Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity
啓示生物科學宣佈雙子座(Gemini)1期臨床研究達到主要安全終點,並顯示統計學顯著的生物標誌物活性。
Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity
啓示生物科學宣佈雙子座(Gemini)1期臨床研究達到主要安全終點,並顯示統計學顯著的生物標誌物活性。
譯文內容由第三人軟體翻譯。